Home LiteratureArticle Details
PMID: 12021376 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Journal of virology ·Vol. 76 ·No. 12 ·2002-06-00 ·Pages 6408-12

Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR

Abstract

A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

MeSH Terms
Animals Antibodies, Monoclonal/administration & dosage,immunology,therapeutic use Antibodies, Viral/administration & dosage,immunology,therapeutic use Disease Models, Animal Ebolavirus/immunology,pathogenicity Guinea Pigs Hemorrhagic Fever, Ebola/immunology,prevention & control,therapy Humans Immunization, Passive Neutralization Tests
Chemicals
Antibodies, Monoclonal Antibodies, Viral
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Parren Paul W H I
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
Geisbert Tom W
Maruyama Toshiaki
Jahrling Peter B
Burton Dennis R
References (33)
33 references, click to expand
  1. An introduction to Ebola: the virus and the disease.
    J Infect Dis. 1999 Feb;179 Suppl 1:ix-xvi PMID: 9988154
  2. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
    Virology. 1998 Jun 20;246(1):134-44 PMID: 9657001
  3. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.
    J Infect Dis. 1999 Feb;179 Suppl 1:S24-7 PMID: 9988161
  4. Pathogenesis of experimental Ebola virus infection in guinea pigs.
    J Infect Dis. 1999 Feb;179 Suppl 1:S203-17 PMID: 9988186
  5. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.
    J Infect Dis. 1999 Feb;179 Suppl 1:S218-23 PMID: 9988187
  6. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
    J Infect Dis. 1999 Feb;179 Suppl 1:S224-34 PMID: 9988188
  7. Recombinant human monoclonal antibodies to Ebola virus.
    J Infect Dis. 1999 Feb;179 Suppl 1:S235-9 PMID: 9988189
  8. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
    J Infect Dis. 1999 Feb;179 Suppl 1:S248-58 PMID: 9988191
  9. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  10. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    J Virol. 1999 Jul;73(7):6024-30 PMID: 10364354
  11. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
    Nat Med. 2000 Feb;6(2):123-5 PMID: 10655088
  12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Nat Med. 2000 Feb;6(2):200-6 PMID: 10655110
  13. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
  14. Epitopes involved in antibody-mediated protection from Ebola virus.
    Science. 2000 Mar 3;287(5458):1664-6 PMID: 10698744
  15. Fighting the Ebola virus.
    Nature. 2000 Nov 30;408(6812):527-8 PMID: 11117724
  16. Development of a preventive vaccine for Ebola virus infection in primates.
    Nature. 2000 Nov 30;408(6812):605-9 PMID: 11117750
  17. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  18. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    J Virol. 2001 Sep;75(17):8340-7 PMID: 11483779
  19. [Isolation and identification of the "Marburg virus"].
    Dtsch Med Wochenschr. 1968 Mar 26;93(12):604-12 PMID: 4966285
  20. A case of Ebola virus infection.
    Br Med J. 1977 Aug 27;2(6086):541-4 PMID: 890413
  21. Ebola haemorrhagic fever in Zaire, 1976.
    Bull World Health Organ. 1978;56(2):271-93 PMID: 307456
  22. Biologic differences between strains of Ebola virus from Zaire and Sudan.
    J Infect Dis. 1983 Feb;147(2):264-7 PMID: 6827142
  23. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response.
    J Exp Med. 1992 Oct 1;176(4):1203-7 PMID: 1402662
  24. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases.
    Infect Agents Dis. 1993 Jun;2(3):118-31 PMID: 8173784
  25. [The isolation of hyperimmune horse serum to the Ebola virus].
    Vopr Virusol. 1994 Mar-Apr;39(2):91-2 PMID: 8017064
  26. Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines.
    Curr Top Microbiol Immunol. 1994;188:221-37 PMID: 7924428
  27. Return to the past: the case for antibody-based therapies in infectious diseases.
    Clin Infect Dis. 1995 Jul;21(1):150-61 PMID: 7578724
  28. [Development and study of the properties of immunoglobulin against Ebola fever].
    Vopr Virusol. 1995 Nov-Dec;40(6):270-3 PMID: 8686265
  29. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.
    Arch Virol Suppl. 1996;11:135-40 PMID: 8800795
  30. [Developing principles for emergency prevention and treatment of Ebola fever].
    Vopr Virusol. 1997 Jan-Feb;42(1):31-4 PMID: 9103042
  31. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Nat Med. 1997 Dec;3(12):1389-93 PMID: 9396610
  32. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants.
    Virology. 1997 Dec 8;239(1):206-16 PMID: 9426460
  33. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.
    J Infect Dis. 1999 Feb;179 Suppl 1:S18-23 PMID: 9988160
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.76.12.6408-6412.2002
Published
2002-06-00
Pages
6408-12
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC136210
Subset
IM
Grants
NIAID NIH HHS · R01 AI048053 · United States
NIAID NIH HHS · AI48053 · United States
External Links
PubMed source DOI: 10.1128/jvi.76.12.6408-6412.2002 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2